Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Byron Ballou is active.

Publication


Featured researches published by Byron Ballou.


Current Medicinal Chemistry | 2005

Fluorescence Imaging of Tumors In Vivo

Byron Ballou; Lauren A. Ernst; Alan S. Waggoner

We review recent progress in tumor imaging in vivo using fluorescent tags, highlight the problems of fluorescence imaging in small animals, discuss recent advances in near-infrared fluorochromes and quantum dots, and point to some future possibilities. GFP-based fluorescence imaging is briefly discussed. The authors believe that improvements in near-infrared fluorochromes are required to enable practical imaging in tissues at centimeter depths.


Cancer Immunology, Immunotherapy | 1995

Tumor labeling in vivo using cyanine-conjugated monoclonal antibodies

Byron Ballou; Gregory W. Fisher; Alan S. Waggoner; Daniel L. Farkas; Jean M. Reiland; Ronald Jaffe; Ratnarkar B. Mujumdar; Swati R. Mujumdar; Thomas R. Hakala

Far-red-emitting cyanine fluorochromes have many properties desirable for in vivo imaging: absorption and emission at wavelengths where blood and tissue are relatively transparent, high quantum yields, and good solubility even at high molar ratios of fluorochrome to antibody. Potentially, conjugation by multiple linkages should minimize hydrolysis in vivo. We conjugated two tumor-targeting monoclonal antibodies: anti-SSEA-1 (IgM, κ) at ratios of 1.2–35 mol dye/mol antibody and 9.2.27 (IgG2a, κ) at 0.6–6 mol dye/mol antibody, using the cyanine fluorochromes Cy3.18, Cy5.18, and Cy5.5.18. Nude mice were inoculated using the SSEA-1-expressing MH-15 teratocarcinoma or the 9.2.27 antigen-expressing SK-MEL-2 melanoma to give tumors at several sites. Conjugated antibody was injected, and mice were imaged immediately after injection and at appropriate intervals thereafter using a standard camera lens, dissecting microscope, or endoscopes. Images were acquired using either an image-intensified video camera or cooled CCD cameras. Immediately after injection, major blood vessels and the heart, liver, and kidneys were readily visualized. After 1 day, tumor-targeting antibody conjugates were concentrated in tumors and there was little circulating conjugate; however, the bladder and kidneys were still visible. Tumors labeled by specific antibody were the most fluorescent tissues at 2 days after injection, but non-specific antibody conjugates did not concentrate in the tumors. The small intestine was weakly visualized by both specific and non-specific antibody conjugates. These data support the possibility of visualizing tumor metastasis by optical means, including currently available endoscopes.


Nano Letters | 2009

Long Term Persistence and Spectral Blue Shifting of Quantum Dots in vivo

James A.J. Fitzpatrick; Susan Andreko; Lauren A. Ernst; Alan S. Waggoner; Byron Ballou; Marcel P. Bruchez

Quantum dots are a powerful fluorophore family with desirable attributes for fluorescence imaging. They have been used in several animal models with direct clinical relevance, including sentinel lymph node mapping, tracing vasculature and lymphatics, and targeting specific lesions for diagnosis and removal. (1-12) Despite significant interest for use in translational applications, little is known about the persistence and long-term fate of quantum dots in vivo. We have observed fluorescence of quantum dots injected into Balb/c and nude mice for up to two-years post injection using both whole-body and microscopic fluorescence techniques. Two-photon spectral microscopy was used to verify the existence of quantum dots within two-year tissues, but also revealed a range of significantly blue-shifted emission peaks with increased bandwidths. Systemically administered quantum dots persist and retain fluorescence for up to two-years in vivo, but with significantly blue-shifted emission.


Biotechnology Progress | 1997

Tumor Detection and Visualization Using Cyanine Fluorochrome‐Labeled Antibodies

Byron Ballou; Gregory W. Fisher; Thomas R. Hakala; Daniel L. Farkas

Tumor localization using fluorescence has been made practical by current improvements in tumor targeting molecules, especially monoclonal antibodies and their derivatives, by the development of convenient near‐infrared emitting fluorochromes and by the availability of digital cameras having high sensitivity in this spectral region. Recent studies in animals have demonstrated that fluorochrome labeling of monoclonal antibodies confers adequate sensitivity and improved resolution. Distribution and catabolism of fluorochrome‐labeled and radiolabeled antibodies are similar. Simultaneous localization of multiple reagents is made possible by labeling with several different near‐infrared emitting fluorochromes; thus background subtraction and differential labeling of multiple tumor‐associated components can be performed. Difficulties in using the fluorochrome labels are mainly related to light scattering and absorption in tissues, but detection of small tumors at depths of several millimeters is feasible. The major medical use of this new technology is likely to be endoscopic location of tumors. Scientific uses include studies of tumor metastasis, uptake and distribution of drugs and tumor‐targeting molecules by tumors, and migration patterns of near‐infrared labeled cells in vivo.


Journal of Biological Chemistry | 1998

Cellular Adhesion Mediated by Factor J, a Complement Inhibitor EVIDENCE FOR NUCLEOLIN INVOLVEMENT

Susana Larrucea; Carolina González-Rubio; Rosario Cambronero; Byron Ballou; Pedro Bonay; Eduardo López-Granados; Philippe Bouvet; Gumersindo Fontán; Manuel Fresno; Margarita López-Trascasa

Factor J (FJ) is a complement inhibitor that acts on the classical and the alternative pathways. We demonstrated FJ-cell interactions in fluid phase by flow cytometry experiments using the cell lines Jurkat, K562, JY, and peripheral blood lymphocytes. FJ bound to plastic plates was able to induce in vitro adhesion of these cells with potency equivalent to fibronectin. As evidence for the specificity of this reaction, the adhesion was blocked by MAJ2, an anti-FJ monoclonal antibody, and by soluble FJ. Attachment of the cells required active metabolism and cytoskeletal integrity. The glycosaminoglycans heparin, heparan sulfate, or chondroitin sulfates A, B, and C inhibited to varying degrees the binding of FJ to cells, as did treatment with chondroitinase ABC. In the search for a putative receptor, a protein of 110 kDa was isolated by affinity chromatography, and microsequence analysis identified this protein as nucleolin. Confocal microscopy evidenced the presence of nucleolin in cell membrane by immunofluorescence with monoclonal (D3) and polyclonal anti-nucleolin antibodies in Jurkat cells. The interaction FJ-nucleolin was evidenced by Western blot and enzyme-linked immunosorbent assay. Furthermore, purified nucleolin and D3 inhibited adhesion of Jurkat cells to immobilized FJ, suggesting that the interaction was specific and that nucleolin mediated the binding.


Molecular Biology Reports | 1996

Internalization of anti-nucleolin antibody into viable HEp-2 cells.

Jau-Shyong Deng; Byron Ballou; Joseph K. Hofmeister

Anti-nucleolin antibodies have been detected in patients with systemic connective tissue diseases (SCTD) including systemic sclerosis (SSc) and systemic lupus erythematosus (SLE). In vivo bound autoantibodies to nucleoli of epidermal keratinocytes have been demonstrated in skin from patients with SCTD. In this study, monoclonal antibody to nucleolin (D-3) was used to determine the distribution of nucleolin in different culture cells including HEp-2, HepG2, HRCC, Molt-4 and Wil2 cells. Nucleolin was found to be present on the surface of HEp-2 and HepG2 cells, but not on the surface of HRCC and lymphoblastoid (Molt-4 and Wil2) cells; in contrast, nucleolin was detected in the nucleoli of all permeabilized cells examined. In immunoprecipitation, using extracts from 32P-labeled HEp-2 cells as antigenic source, cell membrane as well as nuclear nucleolins were found to be phosphorylated with a molecular weight of 105 kDa. Viable HEp-2 and HepG2 cells were cocultured with IgG fraction of D-3 in a CO2 incubator for 1 to 24 h, and then permeabilized with acetone followed by immunofluorescence staining with FITC-labeled goat anti-mouse IgG antibodies. Nucleolar staining was observed in cells after 10 h or longer of coculture. These data indicated that D-3 antibody reacted with cell membrane nucleolin and subsequently gain access into cells in a process related to pinocytosis.


Current Topics in Developmental Biology | 2005

Quantum dot surfaces for use in vivo and in vitro.

Byron Ballou

Publisher Summary This chapter reviews the recent advances in the use of quantum dots for biological imaging and the work done on the effects of chemically varying quantum dot surface properties to improve cellular uptake and imaging in vivo. Quantum dots—first introduced for biological labeling in 1998—have proved to be extraordinarily useful fluorescence reagents that have significant advantages over other types of fluorescent dyes. They combine very high brightness,because of high absorbency and high quantum yields, with unprecedented resistance to photo-bleaching. Emission wavelengths, governed primarily by composition and secondarily by size, range from near‐ultraviolet to infrared. The combination of high brightness, photo-stability, and narrow-emission bandwidths with the ability to excite many colors naturally leads to the possibility of using multicolor combinations of quantum dots to label or “bar‐code” large numbers of different objects. Quantum dots may be used for single‐molecule imaging in living cells. Quantum dots are well suited for two‐photon microscopy. There are potential drawbacks to the use of quantum dots: their large size and high molecular weights may limit applications that require measurement of molecular mobility, and attached quantum dots might interfere with molecular interactions. Since the current generation of quantum dots is composed of toxic heavy metals (CdSe and cadmium telluride [CdTe] cores, with ZnS shells), toxicity might be anticipated if the quantum dots degrade during use.


PLOS ONE | 2012

Nanoparticle Transport from Mouse Vagina to Adjacent Lymph Nodes

Byron Ballou; Susan Andreko; Elvira Osuna-Highley; Michael D. McRaven; Tina Catalone; Marcel P. Bruchez; Thomas J. Hope; Mohamed E. Labib

To test the feasibility of localized intravaginal therapy directed to neighboring lymph nodes, the transport of quantum dots across the vaginal wall was investigated. Quantum dots instilled into the mouse vagina were transported across the vaginal mucosa into draining lymph nodes, but not into distant nodes. Most of the particles were transported to the lumbar nodes; far fewer were transported to the inguinal nodes. A low level of transport was evident at 4 hr after intravaginal instillation, and transport peaked at about 36 hr after instillation. Transport was greatly enhanced by prior vaginal instillation of Nonoxynol-9. Hundreds of micrograms of nanoparticles/kg tissue (ppb) were found in the lumbar lymph nodes at 36 hr post-instillation. Our results imply that targeted transport of microbicides or immunogens from the vagina to local lymph organs is feasible. They also offer an in vivo model for assessing the toxicity of compounds intended for intravaginal use.


PLOS ONE | 2014

Simultaneous multi-species tracking in live cells with quantum dot conjugates.

Mathias P. Clausen; Eva C. Arnspang; Byron Ballou; James E. Bear; B. Christoffer Lagerholm

Quantum dots are available in a range of spectrally separated emission colors and with a range of water-stabilizing surface coatings that offers great flexibility for enabling bio-specificity. In this study, we have taken advantage of this flexibility to demonstrate that it is possible to perform a simultaneous investigation of the lateral dynamics in the plasma membrane of i) the transmembrane epidermal growth factor receptor, ii) the glucosylphospatidylinositol-anchored protein CD59, and iii) ganglioside GM1-cholera toxin subunit B clusters in a single cell. We show that a large number of the trajectories are longer than 50 steps, which we by simulations show to be sufficient for robust single trajectory analysis. This analysis shows that the populations of the diffusion coefficients are heterogeneously distributed for all three species, but differ between the different species. We further show that the heterogeneity is decreased upon treating the cells with methyl-β-cyclodextrin.


Proceedings of the National Academy of Sciences of the United States of America | 2017

Permeation of macromolecules into the renal glomerular basement membrane and capture by the tubules

Marlon G. Lawrence; Michael K. Altenburg; Ryan Sanford; Julian D.S. Willett; Benjamin Bleasdale; Byron Ballou; Jennifer Wilder; Feng Li; Jeffrey H. Miner; Ulla B. Berg; Oliver Smithies

Significance Human kidneys contain ∼2 x 106 glomeruli that produce ∼180 L per day of primary filtrate. Downstream tubules reabsorb most of the water, salt, and desirable low-molecular weight substances, leaving 1 to 2 L per day of urine containing undesirable waste products. Currently, most investigators think that the primary filtrate is low in protein because fluid exiting the glomerulus passes through slits spanned by a diaphragm that acts as a low-porosity molecular sieve. Our experiments challenge this view; they show that size-dependent permeation into the glomerular basement membrane and into a gel-like coat that covers the slits, together with saturable tubular reabsorption, determines which macromolecules reach the urine. The slit diaphragm is essential for capillary structure but may not directly determine glomerular size selectivity. How the kidney prevents urinary excretion of plasma proteins continues to be debated. Here, using unfixed whole-mount mouse kidneys, we show that fluorescent-tagged proteins and neutral dextrans permeate into the glomerular basement membrane (GBM), in general agreement with Ogstons 1958 equation describing how permeation into gels is related to molecular size. Electron-microscopic analyses of kidneys fixed seconds to hours after injecting gold-tagged albumin, negatively charged gold nanoparticles, and stable oligoclusters of gold nanoparticles show that permeation into the lamina densa of the GBM is size-sensitive. Nanoparticles comparable in size with IgG dimers do not permeate into it. IgG monomer-sized particles permeate to some extent. Albumin-sized particles permeate extensively into the lamina densa. Particles traversing the lamina densa tend to accumulate upstream of the podocyte glycocalyx that spans the slit, but none are observed upstream of the slit diaphragm. At low concentrations, ovalbumin-sized nanoparticles reach the primary filtrate, are captured by proximal tubule cells, and are endocytosed. At higher concentrations, tubular capture is saturated, and they reach the urine. In mouse models of Pierson’s or Alport’s proteinuric syndromes resulting from defects in GBM structural proteins (laminin β2 or collagen α3 IV), the GBM is irregularly swollen, the lamina densa is absent, and permeation is increased. Our observations indicate that size-dependent permeation into the lamina densa of the GBM and the podocyte glycocalyx, together with saturable tubular capture, determines which macromolecules reach the urine without the need to invoke direct size selection by the slit diaphragm.

Collaboration


Dive into the Byron Ballou's collaboration.

Top Co-Authors

Avatar

Alan S. Waggoner

Carnegie Mellon University

View shared research outputs
Top Co-Authors

Avatar

Gregory W. Fisher

Carnegie Mellon University

View shared research outputs
Top Co-Authors

Avatar

Marcel P. Bruchez

Carnegie Mellon University

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Daniel L. Farkas

University of Southern California

View shared research outputs
Top Co-Authors

Avatar

Lauren A. Ernst

Carnegie Mellon University

View shared research outputs
Top Co-Authors

Avatar

Susan Andreko

Carnegie Mellon University

View shared research outputs
Top Co-Authors

Avatar

James A.J. Fitzpatrick

Salk Institute for Biological Studies

View shared research outputs
Top Co-Authors

Avatar

Ronald Jaffe

University of Pittsburgh

View shared research outputs
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge